메뉴 건너뛰기
Translational Lung Cancer Research
Volumn 1, Issue 2, 2012, Pages 145-146
EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84907453576     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2012.03.01     Document Type: Note
Times cited : (8)
References (7)
  • 1
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 2
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 3
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
    • (2004) J Clin Oncol , vol.22 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer Sr., P.J.3
  • 4
    • 84855311144 scopus 로고    scopus 로고
    • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    • Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
    • (2012) Lancet Oncol , vol.13 , pp. 33-42
    • Pirker, R.1    Pereira, J.R.2    von Pawel, J.3
  • 5
    • 77949886293 scopus 로고    scopus 로고
    • Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    • Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27.
    • (2010) J Clin Oncol , vol.28 , pp. 918-927
    • Khambata-Ford, S.1    Harbison, C.T.2    Hart, L.L.3
  • 7
    • 51649085865 scopus 로고    scopus 로고
    • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    • Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
    • (2008) N Engl J Med , vol.359 , pp. 1116-1127
    • Vermorken, J.B.1    Mesia, R.2    Rivera, F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.